Abstract

 
 

References (8)



 


 



Black Box Warnings and Drug Safety: Examining the Determinants and Timing of Fda Warning Labels


Allan Begosh


U.S. Food and Drug Administration (FDA)

John Goldsmith


U.S. Department of Health and Human Services - Food and Drug Administration (FDA)

Ed Hass


U.S. Department of Health and Human Services - Food and Drug Administration (FDA)

John A. Vernon


University of North Carolina (UNC) at Chapel Hill; National Bureau of Economic Research (NBER)

Randall Lutter


American Enterprise Institute (AEI); AEI-Brookings Joint Center for Regulatory Studies

Clark Nardinelli


U.S. Department of Health & Human Services

December 2006

NBER Working Paper No. w12803

Abstract:     
Comparing the safety of prescription drugs over time is difficult due to the paucity of reliable quantitative measures of drug safety. Both the academic literature and popular press have focused on drug withdrawals as a proxy for breakdowns in the drug safety system. This metric, however, is problematic because withdrawals are rare events, and they may be influenced by factors beyond a drug's safety profile. In the current paper, we propose a new measure: the incidence and timing of Black Box Warnings (BBWs). BBWs are warnings placed on prescription drug labels when a drug is determined to carry a significant risk of a serious or life-threatening adverse event. Using a unique data set, one that includes all new molecular entities (NMEs) submitted to the FDA between May 1981 and February 2006, and subsequently approved and marketed, we analyze the timing and incidence of BBWs. Our analyses also use data on several drug characteristics likely to affect the probability a new drug will receive a BBW. We draw several conclusions from our analyses. For example, drugs receiving priority FDA review are more likely to have BBWs at the time of approval than NMEs receiving standard review. We also find that early prescription volume and orphan drug status are associated with an increased likelihood of receiving a BBW. We do not, however, find a significant difference in the rate of BBWs across time cohorts. A comparison of NMEs approved before and after the 1992 Prescription Drug User Fee Act (PDUFA), which authorized the payment of user fees from drug manufacturers to the FDA in an effort to expedite new drug application (NDAs) review times, did not reveal a statistically significant difference in the rate of BBWs. Critics of PDUFA maintain that reduced FDA-approval times under PDUFA have compromised drug safety. We do not find empirical support for this contention.

Number of Pages in PDF File: 23

working papers series


Download This Paper

Date posted: January 5, 2007  

Suggested Citation

Begosh, Allan, Goldsmith, John, Hass, Ed, Vernon, John A., Lutter, Randall and Nardinelli, Clark, Black Box Warnings and Drug Safety: Examining the Determinants and Timing of Fda Warning Labels (December 2006). NBER Working Paper No. w12803. Available at SSRN: http://ssrn.com/abstract=955236

Contact Information

Allan Begosh
U.S. Food and Drug Administration (FDA) ( email )
5600 Fishers Lane
Rockville, MD 20857-0001
United States
John Goldsmith
U.S. Department of Health and Human Services - Food and Drug Administration (FDA) ( email )
Office of the Commissioner, Suite 15-36
5600 Fishers Lane
Rockville, MD 20857-0001
United States
HOME PAGE: http://www.fda.gov/
Ed Hass
U.S. Department of Health and Human Services - Food and Drug Administration (FDA) ( email )
5600 Fishers Lane
Rockville, MD 20857-0001
United States
John A. Vernon (Contact Author)
University of North Carolina (UNC) at Chapel Hill ( email )
Chapel Hill, NC 27599
United States
National Bureau of Economic Research (NBER)
1050 Massachusetts Avenue
Cambridge, MA 02138
United States
Randall Lutter
American Enterprise Institute (AEI) ( email )
1150 17th Street, N.W.
Washington, DC 20036
United States
202-862-7177 (Phone)
AEI-Brookings Joint Center for Regulatory Studies
1150 17th Street, N.W.
Washington, DC 20036
United States
Clark Nardinelli
U.S. Department of Health & Human Services ( email )
Washington, DC 20201
United States
Feedback to SSRN (Beta)


Paper statistics
Abstract Views: 764
Downloads: 36
References:  8

© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright
This page was processed by apollo2 in 0.468 seconds